Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Trépo C[au]:

A brief history of hepatitis milestones. Trepo C et al. Liver Int. (2014)

Hepatitis B virus infection. Trépo C et al. Lancet. (2014)

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure. Zeisel MB et al. Gut. (2015)

Search results

Items: 1 to 50 of 723

1.

Perinatal hepatitis B virus transmission in Lao PDR: A prospective cohort study.

Latthaphasavang V, Vanhems P, Ngo-Giang-Huong N, Sibounlang P, Paboriboune P, Malato L, Keoluangkhot V, Thammasack S, Salvadori N, Khamduang W, Steenkeste N, Trépo C, Dény P, Jourdain G.

PLoS One. 2019 Apr 24;14(4):e0215011. doi: 10.1371/journal.pone.0215011. eCollection 2019.

2.

Non-F HBV/HDV-3 coinfection is associated with severe liver disease in Western Brazilian Amazon.

Melo Da Silva E, Kay A, Lobato C, Muwonge R, Zoulim F, Brites C, Parana R, Trepo C.

J Med Virol. 2019 Jun;91(6):1081-1086. doi: 10.1002/jmv.25411. Epub 2019 Feb 11.

PMID:
30695106
3.

Hepatitis C in Laos: A 7-Year Retrospective Study on 1765 Patients.

Paboriboune P, Vial T, Sitbounlang P, Bertani S, Trépo C, Dény P, Babin FX, Steenkeste N, Pineau P, Deharo E.

Virol Sin. 2018 Aug;33(4):295-303. doi: 10.1007/s12250-018-0039-9. Epub 2018 Jun 13.

4.

Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen-Negative Patients.

Höner Zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W, Tangkijvanich P, Su WW, Nieto GEG, Gineste P, Nitcheu J, Crabé S, Stepien S, Manns MP, Trépo C, Wedemeyer H, Cornberg M.

J Infect Dis. 2018 Sep 22;218(9):1480-1484. doi: 10.1093/infdis/jiy350.

PMID:
29893893
5.

Hepatitis B and hepatitis D virus infections in the Central African Republic, twenty-five years after a fulminant hepatitis outbreak, indicate continuing spread in asymptomatic young adults.

Komas NP, Ghosh S, Abdou-Chekaraou M, Pradat P, Al Hawajri N, Manirakiza A, Laghoe GL, Bekondi C, Brichler S, Ouavéné JO, Sépou A, Yambiyo BM, Gody JC, Fikouma V, Gerber A, Abeywickrama Samarakoon N, Alfaiate D, Scholtès C, Martel N, Le Gal F, Lo Pinto H, Amri I, Hantz O, Durantel D, Lesbordes JL, Gordien E, Merle P, Drugan T, Trépo C, Zoulim F, Cortay JC, Kay AC, Dény P.

PLoS Negl Trop Dis. 2018 Apr 26;12(4):e0006377. doi: 10.1371/journal.pntd.0006377. eCollection 2018 Apr.

6.

Anti-E1E2 antibodies status prior therapy favors direct-acting antiviral treatment efficacy.

Virlogeux V, Berthillon P, Bordes I, Larrat S, Crouy S, Scholtès C, Pradat P, Maynard M, Zoulim F, Leroy V, Chemin I, Trépo C, Petit MA.

Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):313-318. doi: 10.1016/j.clinre.2018.02.002. Epub 2018 Mar 16.

PMID:
29551607
7.

Efficiency and Safety of an Early Dose Adjustment of Ribavirin in Patients Infected With Hepatitis C Underexposed to the Drug and Treated With Peginterferon Ribavirin.

Loustaud-Ratti V, Maynard M, Thevenon S, Pradat P, Rousseau A, Alain S, Deny P, Gagnieu MC, Tran A, Dao T, Silvain C, Lunel-Fabiani F, Picard N, Zublena I, Marquet P, Trepo C; RIBAJUSTE Group.

Ther Drug Monit. 2016 Dec;38(6):684-692.

PMID:
27559840
8.

Hepatitis: After HCV cure, HBV cure?

Lucifora J, Trepo C.

Nat Rev Gastroenterol Hepatol. 2015 Jul;12(7):376-8. doi: 10.1038/nrgastro.2015.103. Epub 2015 Jun 23.

PMID:
26100368
9.

Anti-E1E2 antibodies do predict response to triple therapy in treatment-experienced Hepatitis C Virus-cirrhosis cases.

Petit MA, Berthillon P, Pradat P, Arnaud C, Bordes I, Virlogeux V, Maynard M, Bailly F, Zoulim F, Chemin I, Trépo C.

Clin Res Hepatol Gastroenterol. 2015 Dec;39(6):699-704. doi: 10.1016/j.clinre.2015.03.002. Epub 2015 Apr 18.

PMID:
25900002
10.

Towards an HBV cure: state-of-the-art and unresolved questions--report of the ANRS workshop on HBV cure.

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F.

Gut. 2015 Aug;64(8):1314-26. doi: 10.1136/gutjnl-2014-308943. Epub 2015 Feb 10. Review.

PMID:
25670809
11.

HBV/HDV co-infection in the Western Brazilian Amazonia: an intriguing mutation among HDV genotype 3 carriers.

Kay A, Melo da Silva E, Pedreira H, Negreiros S, Lobato C, Braga W, Muwonge R, Dény P, Reis M, Zoulim F, Trepo C, D'Oliveira A Jr, Salcedo JM, Schinoni MI, Parana R.

J Viral Hepat. 2014 Dec;21(12):921-4. doi: 10.1111/jvh.12267. Epub 2014 Jul 9.

PMID:
25040045
12.

Hepatitis B virus infection.

Trépo C, Chan HL, Lok A.

Lancet. 2014 Dec 6;384(9959):2053-63. doi: 10.1016/S0140-6736(14)60220-8. Epub 2014 Jun 18. Review.

PMID:
24954675
13.

Occult HBV infection in Morocco: from chronic hepatitis to hepatocellular carcinoma.

Kitab B, Ezzikouri S, Alaoui R, Nadir S, Badre W, Trepo C, Chemin I, Benjelloun S.

Liver Int. 2014 Jul;34(6):e144-50. doi: 10.1111/liv.12482. Epub 2014 Mar 11.

PMID:
24502524
14.

Diversity of hepatocellular carcinoma clones bearing hematopoietic malignancies-related chromosomal translocation.

Parent R, Plissonnier ML, Bancel B, Liao WL, Rumin S, Asaad R, Till M, Sanlaville D, Zoulim F, Trépo C, Marion MJ.

J Cell Biochem. 2014 Apr;115(4):666-77. doi: 10.1002/jcb.24706.

PMID:
24453043
15.

A brief history of hepatitis milestones.

Trepo C.

Liver Int. 2014 Feb;34 Suppl 1:29-37. doi: 10.1111/liv.12409. Review.

PMID:
24373076
16.

Predictors of the therapeutic response in hepatitis C. A 2013 update.

Arnaud C, Trépo C, Petit MA.

Clin Res Hepatol Gastroenterol. 2014 Feb;38(1):12-7. doi: 10.1016/j.clinre.2013.08.003. Epub 2013 Nov 21. Review.

PMID:
24268305
17.

Pretreatment predictive factors for hepatitis C therapy outcome: relevance of anti-E1E2 antibodies compared to IP-10 and IL28B genotypes.

Arnaud C, Pradat P, Spaziante M, Berthillon P, Maynard M, Taliani G, Chemin I, Trépo C, Petit MA.

Antivir Ther. 2013;18(8):1027-32. doi: 10.3851/IMP2671. Epub 2013 Aug 15.

PMID:
23948510
18.

Improved rolling circle amplification (RCA) of hepatitis B virus (HBV) relaxed-circular serum DNA (RC-DNA).

Martel N, Gomes SA, Chemin I, Trépo C, Kay A.

J Virol Methods. 2013 Nov;193(2):653-9. doi: 10.1016/j.jviromet.2013.07.045. Epub 2013 Aug 5.

PMID:
23928222
19.

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arastéh K, Bourlière M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G; BI 207127 Study Group.

Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35. doi: 10.1128/AAC.00565-13. Epub 2013 Jul 15.

20.

The state of hepatitis B and C in the Mediterranean and Balkan countries: report from a summit conference.

Hatzakis A, Van Damme P, Alcorn K, Gore C, Benazzouz M, Berkane S, Buti M, Carballo M, Cortes Martins H, Deuffic-Burban S, Dominguez A, Donoghoe M, Elzouki AN, Ben-Alaya Bouafif N, Esmat G, Esteban R, Fabri M, Fenton K, Goldberg D, Goulis I, Hadjichristodoulou C, Hatzigeorgiou T, Hamouda O, Hasurdjiev S, Hughes S, Kautz A, Malik M, Manolakopoulos S, Matičič M, Papatheodoridis G, Peck R, Peterle A, Potamitis G, Prati D, Roudot-Thoraval F, Reic T, Sharara A, Shennak M, Shiha G, Shouval D, Sočan M, Thomas H, Thursz M, Tosti M, Trépo C, Vince A, Vounou E, Wiessing L, Manns M.

J Viral Hepat. 2013 Aug;20 Suppl 2:1-20. doi: 10.1111/jvh.12120. Erratum in: J Viral Hepat. 2013 Oct;20(10):744. Hadjichristodoulou, T [corrected to Hadjichristodoulou, C].

PMID:
23827008
21.

Discovery of naturally occurring transmissible chronic hepatitis B virus infection among Macaca fascicularis from Mauritius Island.

Dupinay T, Gheit T, Roques P, Cova L, Chevallier-Queyron P, Tasahsu SI, Le Grand R, Simon F, Cordier G, Wakrim L, Benjelloun S, Trépo C, Chemin I.

Hepatology. 2013 Nov;58(5):1610-20. doi: 10.1002/hep.26428. Epub 2013 Sep 17.

PMID:
23536484
22.

Farnesoid X receptor targeting for hepatitis C: study protocol for a proof-of-concept trial.

Scholtes C, André P, Trépo C, Cornu C, Remontet L, Ecochard R, Bejan-Angoulvant T, Gueyffier F.

Therapie. 2012 Sep-Oct;67(5):423-7. doi: 10.2515/therapie/2012058. Epub 2012 Dec 18.

PMID:
23241251
23.

Identification of novel recombinants of hepatitis B virus genotypes F and G in human immunodeficiency virus-positive patients from Argentina and Brazil.

Araujo NM, Araujo OC, Silva EM, Villela-Nogueira CA, Nabuco LC, Parana R, Bessone F, Gomes SA, Trepo C, Kay A.

J Gen Virol. 2013 Jan;94(Pt 1):150-8. doi: 10.1099/vir.0.047324-0. Epub 2012 Oct 17.

PMID:
23079380
24.

Variability in the precore and core promoter regions of HBV strains in Morocco: characterization and impact on liver disease progression.

Kitab B, Essaid El Feydi A, Afifi R, Trepo C, Benazzouz M, Essamri W, Zoulim F, Chemin I, Alj HS, Ezzikouri S, Benjelloun S.

PLoS One. 2012;7(8):e42891. doi: 10.1371/journal.pone.0042891. Epub 2012 Aug 14.

25.

Different patterns of decompensation in patients with alcoholic vs. non-alcoholic liver cirrhosis.

Wiegand J, Kühne M, Pradat P, Mössner J, Trepo C, Tillmann HL.

Aliment Pharmacol Ther. 2012 Jun;35(12):1443-50. doi: 10.1111/j.1365-2036.2012.05108.x. Epub 2012 Apr 24.

26.

Markers of inflammation and fibrosis in alcoholic hepatitis and viral hepatitis C.

Neuman MG, Schmilovitz-Weiss H, Hilzenrat N, Bourliere M, Marcellin P, Trepo C, Mazulli T, Moussa G, Patel A, Baig AA, Cohen L.

Int J Hepatol. 2012;2012:231210. doi: 10.1155/2012/231210. Epub 2012 Feb 22.

27.

Probable corticosteroid-induced reactivation of latent hepatitis B virus infection in an HIV-positive patient involving immune escape.

Martel N, Cotte L, Trabaud MA, Trepo C, Zoulim F, Gomes SA, Kay A.

J Infect Dis. 2012 Jun;205(11):1757-61. doi: 10.1093/infdis/jis268. Epub 2012 Mar 29.

PMID:
22459735
28.

First presentation for care of HIV-infected patients with low CD4 cell count in Lyon, France: risk factors and consequences for survival.

Touré A, Khanafer N, Baratin D, Bailly F, Livrozet JM, Trepo C, Peyramond D, Touraine JL, Vanhems P.

AIDS Care. 2012;24(10):1272-6. doi: 10.1080/09540121.2012.656574. Epub 2012 Mar 15.

PMID:
22416893
29.

Rapid and strong antiviral activity of the non-nucleosidic NS5B polymerase inhibitor BI 207127 in combination with peginterferon alfa 2a and ribavirin.

Larrey D, Lohse AW, de Ledinghen V, Trepo C, Gerlach T, Zarski JP, Tran A, Mathurin P, Thimme R, Arastéh K, Trautwein C, Cerny A, Dikopoulos N, Schuchmann M, Heim MH, Gerken G, Stern JO, Wu K, Abdallah N, Girlich B, Scherer J, Berger F, Marquis M, Kukolj G, Böcher W, Steffgen J.

J Hepatol. 2012 Jul;57(1):39-46. doi: 10.1016/j.jhep.2012.02.015. Epub 2012 Mar 10.

PMID:
22414766
30.

Hepatitis B virus impairs TLR9 expression and function in plasmacytoid dendritic cells.

Vincent IE, Zannetti C, Lucifora J, Norder H, Protzer U, Hainaut P, Zoulim F, Tommasino M, Trépo C, Hasan U, Chemin I.

PLoS One. 2011;6(10):e26315. doi: 10.1371/journal.pone.0026315. Epub 2011 Oct 25.

31.

Mutations in TP53 and CTNNB1 in Relation to Hepatitis B and C Infections in Hepatocellular Carcinomas from Thailand.

Galy O, Chemin I, Le Roux E, Villar S, Le Calvez-Kelm F, Lereau M, Gouas D, Vieco B, Suarez I, Navas MC, Chevallier M, Norder H, Srivatanakul P, Karalak A, Sangrajrang S, Trépo C, Hainaut P.

Hepat Res Treat. 2011;2011:697162. doi: 10.1155/2011/697162. Epub 2011 Jun 30.

32.

Evolution of Hepatitis B and C serum markers: a still challenging issue.

Chemin I, Trépo C.

Liver Int. 2011 Aug;31(7):905-7. doi: 10.1111/j.1478-3231.2011.02479.x. Epub 2011 Mar 16. No abstract available.

PMID:
21733079
33.

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G.

Gastroenterology. 2011 Sep;141(3):890-899.e1-4. doi: 10.1053/j.gastro.2011.06.009. Epub 2011 Jun 13.

PMID:
21699798
34.

Hepatitis B genotypes/subgenotypes and MHR variants among Moroccan chronic carriers.

Kitab B, El Feydi AE, Afifi R, Derdabi O, Cherradi Y, Benazzouz M, Rebbani K, Brahim I, Salih Alj H, Zoulim F, Trepo C, Chemin I, Ezzikouri S, Benjelloun S.

J Infect. 2011 Jul;63(1):66-75. doi: 10.1016/j.jinf.2011.05.007. Epub 2011 May 17.

PMID:
21640384
35.

Pharmacological exposure to ribavirin: a key player in the complex network of factors implicated in virological response and anaemia in hepatitis C treatment.

Loustaud-Ratti V, Carrier P, Rousseau A, Maynard M, Babany G, Alain S, Trépo C, De Ledinghen V, Bourlière M, Pol S, Di Martino V, Zarski JP, Pinta A, Sautereau D, Marquet P; OPTIRIB group.

Dig Liver Dis. 2011 Nov;43(11):850-5. doi: 10.1016/j.dld.2011.04.002. Epub 2011 May 18. Review.

PMID:
21596633
36.

Long-term propagation of serum hepatitis C virus (HCV) with production of enveloped HCV particles in human HepaRG hepatocytes.

Ndongo-Thiam N, Berthillon P, Errazuriz E, Bordes I, De Sequeira S, Trépo C, Petit MA.

Hepatology. 2011 Aug;54(2):406-17. doi: 10.1002/hep.24386. Epub 2011 Jun 30.

PMID:
21520209
37.

Impact of patatin-like phospholipase-3 (rs738409 C>G) polymorphism on fibrosis progression and steatosis in chronic hepatitis C.

Trépo E, Pradat P, Potthoff A, Momozawa Y, Quertinmont E, Gustot T, Lemmers A, Berthillon P, Amininejad L, Chevallier M, Schlué J, Kreipe H, Devière J, Manns M, Trépo C, Sninsky J, Wedemeyer H, Franchimont D, Moreno C.

Hepatology. 2011 Jul;54(1):60-9. doi: 10.1002/hep.24350.

PMID:
21488075
38.

Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease.

Trépo E, Potthoff A, Pradat P, Bakshi R, Young B, Lagier R, Moreno C, Verset L, Cross R, Degré D, Lemmers A, Gustot T, Berthillon P, Rosenberg W, Trépo C, Sninsky J, Adler M, Wedemeyer H.

J Hepatol. 2011 Jul;55(1):38-44. doi: 10.1016/j.jhep.2010.10.018. Epub 2010 Nov 23.

PMID:
21145859
39.

Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection.

Manns MP, Bourlière M, Benhamou Y, Pol S, Bonacini M, Trepo C, Wright D, Berg T, Calleja JL, White PW, Stern JO, Steinmann G, Yong CL, Kukolj G, Scherer J, Boecher WO.

J Hepatol. 2011 Jun;54(6):1114-22. doi: 10.1016/j.jhep.2010.08.040. Epub 2010 Nov 11.

PMID:
21145839
40.

Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC).

Franceschi S, Lise M, Trépo C, Berthillon P, Chuang SC, Nieters A, Travis RC, Vermeulen R, Overvad K, Tjønneland A, Olsen A, Bergmann MM, Boeing H, Kaaks R, Becker N, Trichopoulou A, Lagiou P, Bamia C, Palli D, Sieri S, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita B, Peeters PH, Rodríguez L, Barroso LL, Dorronsoro M, Sánchez MJ, Navarro C, Barricarte A, Regnér S, Borgquist S, Melin B, Hallmans G, Khaw KT, Wareham N, Rinaldi S, Hainaut P, Riboli E, Vineis P.

Cancer Epidemiol Biomarkers Prev. 2011 Jan;20(1):208-14. doi: 10.1158/1055-9965.EPI-10-0889. Epub 2010 Nov 23.

41.

Pharmacological inhibition of Frizzled-7 displays anti-tumor properties in hepatocellular carcinoma.

Nambotin SB, Lefrancois L, Sainsily X, Berthillon P, Kim M, Wands JR, Chevallier M, Jalinot P, Scoazec JY, Trepo C, Zoulim F, Merle P.

J Hepatol. 2011 Feb;54(2):288-99. doi: 10.1016/j.jhep.2010.06.033. Epub 2010 Sep 16.

PMID:
21055837
42.

High rate of adefovir-lamivudine combination therapy in nucleoside-naïve patients with chronic hepatitis B in France: results of a national survey in 1730 patients.

Marcellin P, Cadranel JF, Fontanges T, Poynard T, Pol S, Trepo C, Blin P, Bregman B, Schmidely N, Roudot-Thoraval F, Zarski JP.

Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1290-6.

PMID:
20964259
43.

Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus.

Ndongo N, Berthillon P, Pradat P, Vieux C, Bordes I, Berby F, Maynard M, Zoulim F, Trépo C, Petit MA.

Hepatology. 2010 Nov;52(5):1531-42. doi: 10.1002/hep.23862.

PMID:
20890942
44.

A randomized trial of viral hepatitis prevention among underprivileged people in the Lyon area of France.

Sahajian F, Bailly F, Vanhems P, Fantino B, Vannier-Nitenberg C, Fabry J, Trepo C; Members of ADHEC.

J Public Health (Oxf). 2011 Jun;33(2):182-92. doi: 10.1093/pubmed/fdq071. Epub 2010 Sep 27.

PMID:
20876189
45.

[Results of a satisfaction survey carried out among patients living with the virus of human immunodeficiency (HIV) following therapeutic education sessions].

Feutrier C, Schlienger I, Veysset F, Viollet C, Bret M, Zoulim F, Trepo C, Leboucher G.

Ann Pharm Fr. 2010 Sep;68(5):306-17. doi: 10.1016/j.pharma.2010.05.004. Epub 2010 Jul 6. French.

PMID:
20850002
46.

Prevalence and challenges of liver diseases in patients with chronic hepatitis C virus infection.

Jacobson IM, Davis GL, El-Serag H, Negro F, Trépo C.

Clin Gastroenterol Hepatol. 2010 Nov;8(11):924-33; quiz e117. doi: 10.1016/j.cgh.2010.06.032. Epub 2010 Aug 14. Review.

PMID:
20713178
47.

Expression of E1E2 on hepatitis C RNA-containing particles released from primary cultured human hepatocytes derived from infected cirrhotic livers.

Ndongo N, Selliah S, Berthillon P, Raymond VA, Trépo C, Bilodeau M, Petit MA.

Intervirology. 2011;54(1):1-9. doi: 10.1159/000318886. Epub 2010 Aug 6.

48.

Management of nonresponsive hepatitis C.

Bailly F, Ahmed SN, Pradat P, Trepo C.

Expert Rev Anti Infect Ther. 2010 Apr;8(4):379-95. doi: 10.1586/eri.10.17. Review.

PMID:
20377334
49.

Hepatitis B virus replication in primary macaque hepatocytes: crossing the species barrier toward a new small primate model.

Lucifora J, Vincent IE, Berthillon P, Dupinay T, Michelet M, Protzer U, Zoulim F, Durantel D, Trepo C, Chemin I.

Hepatology. 2010 Jun;51(6):1954-60. doi: 10.1002/hep.23602.

PMID:
20301206
50.

Sarcoidosis and hepatitis C: clinical description of 11 cases.

Faurie P, Broussolle C, Zoulim F, Trepo C, Sève P.

Eur J Gastroenterol Hepatol. 2010 Aug;22(8):967-72. doi: 10.1097/MEG.0b013e32833834bc.

PMID:
20216423

Supplemental Content

Support Center